

# Stanford

---



## Amy Leslie

Postdoctoral Scholar, Urology

### Bio

---

#### BIO

Dr. Amy R. Leslie is a postdoctoral fellow at Stanford University School of Medicine in the Department of Urology in Dr. James D. Brooks's lab. Dr. Leslie received their Ph.D. from UC Davis in Integrative Pathobiology in Dr. Allen C. Gao's lab and B.S. from UC Santa Cruz in Biochemistry and Molecular Biology. Before coming to Stanford, Amy's prior research focused on characterization of therapeutic resistance in advanced stages of prostate cancer. Currently, Dr. Leslie is investigating how prostate cancer cells evade the immune response through glycosylation alterations to the cancer cell surface using in vitro and in vivo approaches.

#### BOARDS, ADVISORY COMMITTEES, PROFESSIONAL ORGANIZATIONS

- Associate Member, American Association of Cancer Research (AACR) (2023 - present)
- Research Scientist Member, American Urological Association (AUA) (2025 - present)

#### STANFORD ADVISORS

- James Brooks, Postdoctoral Faculty Sponsor

### Publications

---

#### PUBLICATIONS

- **IGFBP3-SphK1/S1P Signaling Axis Drives Enzalutamide Resistance in Advanced Prostate Cancer.** *Molecular cancer therapeutics*  
Leslie, A. R., Ning, S., Sharifi, M., Schaaf, Z. A., Maine, J. P., Lou, W., Leslie, K. D., Liu, C., Xu, H., Lombard, A. P., Chen, H. W., Parikh, M., Dall'Era, et al  
2025
- **Steroid Sulfatase Regulates Metabolic Reprogramming in Advanced Prostate Cancer.** *Cancers*  
Sharifi, M., Armstrong, C. M., Ning, S., Leslie, A. R., Schaaf, Z. A., Maine, J. P., Lou, W., Li, P. K., Xu, H., Liu, C., Gao, A. C.  
2025; 17 (12)
- **LX1 Dual Targets AR Variants and AKR1C3 in Advanced Prostate Cancer Therapy.** *Cancer research*  
Ning, S., Armstrong, C. M., Xing, E., Leslie, A. R., Gao, R. Y., Sharifi, M., Schaaf, Z. A., Lou, W., Han, X., Xu, D. H., Yang, R., Cheng, J., Mohammed, et al  
2024; 84 (21): 3617-3628
- **PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells.** *Cancer research communications*  
Schaaf, Z. A., Ning, S., Leslie, A. R., Sharifi, M., Gao, R. Y., Maine, J. P., Lou, W., Lombard, A. P., Liu, C., Yu, A. M., Mitsiades, N., Gao, A. C.  
2024; 4 (11): 2976-2985
- **IGFBP3 promotes resistance to Olaparib via modulating EGFR signaling in advanced prostate cancer.** *iScience*  
Leslie, A. R., Ning, S., Armstrong, C. M., D'Abronzio, L. S., Sharifi, M., Schaaf, Z. A., Lou, W., Liu, C., Evans, C. P., Lombard, A. P., Gao, A. C.

---

2024; 27 (2): 108984

- **Therapeutic Resistance Models and Treatment Sequencing in Advanced Prostate Cancer.** *Cancers*  
Schaaf, Z. A., Ning, S., Leslie, A. R., Sharifi, M., Han, X., Armstrong, C., Lou, W., Lombard, A. P., Liu, C., Gao, A. C.  
2023; 15 (21)
- **Wntless expression promotes lineage plasticity and is associated with neuroendocrine prostate cancer.** *American journal of clinical and experimental urology*  
D'Abronzio, L. S., Lombard, A. P., Ning, S., Armstrong, C. M., Leslie, A. R., Sharifi, M., Schaaf, Z. A., Lou, W., Gao, A. C.  
2022; 10 (5): 299-310
- **Bioengineered BERA-Wnt5a siRNA Targeting Wnt5a/FZD2 Signaling Suppresses Advanced Prostate Cancer Tumor Growth and Enhances Enzalutamide Treatment.** *Molecular cancer therapeutics*  
Ning, S., Liu, C., Lou, W., Yang, J. C., Lombard, A. P., D'Abronzio, L. S., Batra, N., Yu, A. M., Leslie, A. R., Sharifi, M., Evans, C. P., Gao, A. C.  
2022; 21 (10): 1594-1607
- **Activation of neural lineage networks and ARHGEF2 in enzalutamide-resistant and neuroendocrine prostate cancer and association with patient outcomes.** *Communications medicine*  
Ning, S., Zhao, J., Lombard, A. P., D'Abronzio, L. S., Leslie, A. R., Sharifi, M., Lou, W., Liu, C., Yang, J. C., Evans, C. P., Corey, E., Chen, H. W., Yu, et al  
2022; 2: 118
- **Olaparib-Induced Senescence Is Bypassed through G2-M Checkpoint Override in Olaparib-Resistant Prostate Cancer.** *Molecular cancer therapeutics*  
Lombard, A. P., Armstrong, C. M., D'Abronzio, L. S., Ning, S., Leslie, A. R., Sharifi, M., Lou, W., Evans, C. P., Dall'Era, M., Chen, H. W., Chen, X., Gao, A. C.  
2022; 21 (4): 677-685